-
Mashup Score: 6
Background PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of s…
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Angiotensin‐Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure - 2 year(s) ago
Aims Patients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin/neprilysin in…
Source: Wiley Online LibraryCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 13
Background: Sacubitril/valsartan is a first-in-class angiotensin-receptor neprilysin inhibitor used to treat heart failure. The evidence for this novel medication is largely based on one pivotal phase III trial which was stopped early due to significant …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
Domains of disease burden are clinically relevant features that influence the prognosis and treatment of patients with HF. The therapeutic benefits of sacubitril/valsartan vary according to the balance of components of disease burden, across different ranges of left ventricular ejection fraction.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 15Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction - 3 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2021 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.ScienceDirect ® is a registered…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
A summary of differences between women and men in the PROVE‐HF study.
Source: Wiley Online LibraryCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Click on the article title to read more.
Source: Wiley Online LibraryCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
Background: Among patients with heart failure and reduced ejection fraction (HFrEF, left ventricular [LV] EF ≤40%) sacubitril/valsartan (S/V) treatment is associated with improved health status and r
Source: Circulation: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet
PARAGON-HF analysis suggests #SacubitrilValsartan benefits women with preserved ejection fraction similarly to men, with reduced risk of readmissions or deaths compared to ACE/ARB (HR: 0.74). #AHAJournals https://t.co/CHapEpXhbo https://t.co/Mz7ZlmyAd7